Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Reliance Global Group, Inc.

Ticker
EZRA
Sector
Industry
Report date
November 17, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news highlights Reliance Global Group's growth in insurance premiums and health insurance policies through its RELI Exchange platform, capital raising activities, and strategic moves into AI diagnostics.

Recent developments:
  • Reliance Global Group announced a 36% year-over-year increase in personal lines property and casualty written premium through RELI Exchange [N15].
  • The company reported a 72% increase in health insurance policies written through RELI Exchange during the 2025 open enrollment period [N15].
  • Reliance Global Group announced the pricing of a $2 million public offering in January 2026 [N14].
  • The company plans to acquire a majority stake in AI breath diagnostics firm Scentech [N13].
Overview

Reliance Global Group, Inc. operates in insurance brokerage and InsurTech, providing personal lines property and casualty insurance and health insurance policies through its RELI Exchange platform. In 2026, the company expanded into technology and life sciences sectors via subsidiaries EZRA International Group LLC and LifeSci Global Group LLC, targeting investments in emerging technology fields and healthcare-related companies. The company has limited operating experience in these new sectors and faces risks associated with early-stage investments, regulatory complexities, and integration challenges. Reliance Global Group maintains Nasdaq listing compliance efforts and has reported positive financial results with strong liquidity as of Q3 2026.

Executive summary

Reliance Global Group, Inc. is a Nasdaq-listed company (ticker EZRA) engaged primarily in insurance brokerage and InsurTech, with recent strategic expansions into technology and life sciences sectors. The company reported Q3 2026 revenue of approximately $1.84 million and net income of $3.35 million, with strong liquidity ratios as of September 30, 2026. Recent SEC filings disclose risks related to Nasdaq listing compliance, new sector expansions, and investments in early-stage companies, including a full write-down of its investment in Enquantum Ltd. The company has announced growth in insurance premiums through its RELI Exchange platform and is pursuing acquisitions and capital raises to support its diversified business model. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for EZRA

Bull case model:

Reliance Global Group's growth in insurance premiums through RELI Exchange and its strategic expansion into technology and life sciences sectors could diversify revenue streams and enhance long-term business value. The company's strong liquidity ratios and recent capital raises provide financial flexibility to pursue acquisitions and investments. Successful execution of the Scale51 operating model and LifeSci Global Group platform may enable the company to capitalize on emerging technology and healthcare opportunities, potentially strengthening its market position.

Bear case model:

The company's limited experience in technology and life sciences sectors introduces execution risks, including challenges in identifying suitable investments, conducting diligence, and managing portfolio companies. The full write-down of the Enquantum investment highlights the speculative nature of early-stage technology ventures. Regulatory complexities and supply chain risks in the life sciences sector, particularly for Innervate's radiopharmaceutical products, may delay or impair commercialization. Nasdaq listing compliance risks and potential delisting could adversely affect liquidity and capital access.

Moat:

Reliance Global Group's moat is primarily based on its established insurance brokerage and InsurTech platform, RELI Exchange, which has demonstrated growth in written premiums and health insurance policies. The company's expansion into technology and life sciences sectors is nascent, with limited operating history and significant execution risks. The moat in these new sectors depends on successful investment selection, regulatory navigation, and integration capabilities, which are currently unproven. The company's liquidity position and Nasdaq listing status support operational continuity but do not constitute a strong competitive moat in the new sectors.

Risks overview
Risks summary
The most significant risks relate to Nasdaq listing compliance, execution challenges in new technology and life sciences sectors, and the speculative nature of early-stage investments with regulatory and operational complexities.
Risks details:

• Nasdaq Listing Compliance Risk: The company has recently been below Nasdaq's minimum Market Value of Listed Securities threshold and faces potential delisting risks if compliance is not maintained, which could adversely affect liquidity and capital access [S2].
• Execution Risk in New Sectors: Limited operating experience in technology and life sciences sectors increases risks related to investment selection, integration, and management of new business lines [S2].
• Investment Risk in Early-Stage Companies: Investments in early-stage companies like Enquantum and Innervate are highly speculative, with risks of loss, regulatory hurdles, and operational challenges [S2].
• Related Party Transactions and Conflicts of Interest: Ownership structure of LifeSci Global Group and overlapping management roles create potential conflicts that may affect decision-making and expose the company to regulatory or reputational risks [S2].
• Regulatory and Supply Chain Risks in Life Sciences: Innervate's radiopharmaceutical products face complex regulatory regimes and supply constraints for medical radioisotopes, which could delay development and commercialization [S2].

FINAL FORECAST FOR EZRA

Final take one line
Reliance Global Group, Inc. exhibits very high visibility with detailed SEC disclosures and recent news on its diversified insurance, technology, and life sciences businesses.
Final take 12 to 24 month view

Business trends: Expansion into technology and life sciences sectors alongside growth in insurance premiums through RELI Exchange.
Execution milestones: Completion of Q3 2026 financial reporting with positive net income and liquidity; launch of Scale51 operating model; formation of LifeSci Global Group.
Key risks: Nasdaq listing compliance challenges, execution risks in new sectors, speculative early-stage investments, regulatory complexities, and related party conflicts.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Reliance Global Group, Inc. is a publicly traded company listed on the Nasdaq Capital Market under the ticker EZRA [S1].
  • As of March 10, 2026, the company had 21,253,013 shares of common stock outstanding [S1].
  • The company operates in insurance brokerage and InsurTech businesses and has expanded into technology and life sciences sectors through subsidiaries EZRA International Group LLC and LifeSci Global Group LLC [S2].
  • The company launched EZRA International Group and introduced the Scale51 operating model in January 2026 to pursue majority ownership in technology-driven businesses, including post-quantum cryptography, cybersecurity, and AI [S2].
  • Reliance Global Group has limited operating experience in technology and life sciences sectors, which represent new lines of business [S2].
  • The company has invested in early-stage technology company Enquantum Ltd., which ceased operations in Q3 2026, resulting in a write-down of the investment to zero [S2].
  • Reliance Global Group formed LifeSci Global Group (LGG) in April 2026 to pursue investments in healthcare and life sciences, including an initial investment in Innervate, an early-stage radiopharmaceutical company [S2].
  • LGG is majority-owned by Reliance Global Group (51%) with a minority partner owning 49%, creating related party transactions and potential conflicts of interest [S2].
  • Innervate is subject to specialized regulatory regimes and supply chain risks related to medical radioisotopes, which could affect development and commercialization [S2].
  • The company reported financial figures for the quarter ended September 30, 2026: revenue of $1,842,997, net income of $3,347,438, basic EPS of $2.39, and diluted EPS of $2.34 [S2].
  • Liquidity ratios as of September 30, 2026, include a current ratio of 5.38 and a cash ratio of 6.38, with cash and equivalents of $10,018,000 and current liabilities of $1,570,094 [S2].
  • The company received a Nasdaq notice in December 2025 for non-compliance with minimum bid price but regained compliance by June 2026 [S2].
  • Risks include potential Nasdaq delisting due to market value of listed securities below $5 million, risks related to new technology and life sciences investments, and operational challenges integrating new business lines [S2].
  • The company announced a 36% year-over-year increase in personal lines property and casualty written premium through its RELI Exchange platform and a 72% increase in health insurance policies written during 2025 open enrollment [N15].
  • Reliance Global Group announced a $2 million public offering in January 2026 [N14].
  • The company plans majority stake acquisition in AI breath diagnostics firm Scentech [N13].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K/A
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-17 | www.nasdaq.com | Cumberland Pharmaceuticals Inc. Announces Phase 2a ASSIST-SSc Trial Top-Line Results | https://www.nasdaq.com/articles/cumberland-pharmaceuticals-inc-announces-phase-2a-assist-ssc-trial-top-line-results
  • N2 | 2026-11-17 | www.nasdaq.com | Western Digital Corporation Enters into $1.5 billion Revolving Credit Agreement | https://www.nasdaq.com/articles/western-digital-corporation-enters-15-billion-revolving-credit-agreement
  • N3 | 2026-11-17 | www.nasdaq.com | United Maritime Corporation Reports Third Quarter 2026 Net Income of $3.2 Million and Doubles Quarterly Cash Dividend to $0.20 Per Share | https://www.nasdaq.com/articles/united-maritime-corporation-reports-third-quarter-2026-net-income-32-million-and-doubles
  • N4 | 2026-11-17 | www.nasdaq.com | Mid-America Apartment Communities, Inc. Details $760.0 Million Active Development Pipeline and Financial Outlook | https://www.nasdaq.com/articles/mid-america-apartment-communities-inc-details-7600-million-active-development-pipeline-and
  • N5 | 2026-11-17 | www.nasdaq.com | Seanergy Maritime Holdings Corp. Reports Record Nine-Month Net Income of $61.9 Million and Raises Quarterly Dividend to $0.40 Per Share | https://www.nasdaq.com/articles/seanergy-maritime-holdings-corp-reports-record-nine-month-net-income-619-million-and
  • N6 | 2026-11-17 | www.nasdaq.com | Cumberland Pharmaceuticals Inc. Announces Plans to File New Drug Application for Ifetroban DMD Program | https://www.nasdaq.com/articles/cumberland-pharmaceuticals-inc-announces-plans-file-new-drug-application-ifetroban-dmd
  • N7 | 2026-11-17 | www.nasdaq.com | Walmart Reports Earnings on Nov. 19 2026. Here's What Investors Should Be Watching. | https://www.nasdaq.com/articles/walmart-reports-earnings-nov-19-2026-heres-what-investors-should-be-watching
  • N8 | 2026-11-17 | www.nasdaq.com | Aqua Metals, Inc. Reports Third Quarter 2026 Financial Results and Establishes Offtake Pathways | https://www.nasdaq.com/articles/aqua-metals-inc-reports-third-quarter-2026-financial-results-and-establishes-offtake
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine